Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Avalo Therapeutics, Inc. - Common Stock (NQ:AVTX)

3.770 -0.140 (-3.58%)
Streaming Delayed Price Updated: 1:37 PM EDT, May 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Avalo Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates
From Avalo Therapeutics
Via GlobeNewswire
Avalo Therapeutics to Participate in The Citizens Life Sciences Conference
From Avalo Therapeutics
Via GlobeNewswire
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board
From Avalo Therapeutics
Via GlobeNewswire
Avalo Therapeutics 'Represents An Attractive Pure-Play,' Analyst Initiates Coverage With Over 300% Stock Upside
Avalo Therapeutics' AVTX-009 is advancing in hidradenitis suppurativa, with Phase 2 data expected in 2026. Stifel initiates coverage with a $36 price target. 
Via Benzinga
This Clearway Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Via Benzinga
Avalo Reports 2024 Financial Results and Recent Business Updates
From Avalo Therapeutics
Via GlobeNewswire
This CoStar Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Via Benzinga
Avalo Therapeutics to Participate in Upcoming Investor Conferences
From Avalo Therapeutics
Via GlobeNewswire
Avalo Therapeutics to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference
From Avalo Therapeutics
Via GlobeNewswire
Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer
From Avalo Therapeutics
Via GlobeNewswire
Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants
From Avalo Therapeutics
Via GlobeNewswire
Avalo Therapeutics to Present at Upcoming Investor Conferences
From Avalo Therapeutics
Via GlobeNewswire
Avalo Reports Third Quarter 2024 Financial Results and Recent Business Updates
From Avalo Therapeutics
Via GlobeNewswire
Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa
From Avalo Therapeutics
Via GlobeNewswire
Avalo Announces Participation in September Investor Conferences
From Avalo Therapeutics
Via GlobeNewswire
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
AVTX Stock Earnings: Avalo Therapeutics Misses EPS for Q2 2024
AVTX stock results show that Avalo Therapeutics missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates
From Avalo Therapeutics
Via GlobeNewswire
The 3 Best Personalized Nutrition Stocks to Buy Now
Explore personalized nutrition stocks capitalizing on AI, machine learning and genetic profiling to provide targeted dietary solutions. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer
From Avalo Therapeutics
Via GlobeNewswire
Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa
From Avalo Therapeutics
Via GlobeNewswire
Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer
From Avalo Therapeutics
Via GlobeNewswire
Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit
From Avalo Therapeutics
Via GlobeNewswire
AVTX Stock Earnings: Avalo Therapeutics Misses EPS, Beats Revenue for Q4 2023
AVTX stock results show that Avalo Therapeutics missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
AVTX Stock Earnings: Avalo Therapeutics Misses EPS for Q1 2024
AVTX stock results show that Avalo Therapeutics missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates
From Avalo Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Avalo Therapeutics' Newly Acquired Ex-Eli Lilly Drug Could Stand Out In Competitive Hidradenitis Suppurativa Market, Analyst Upgrades
Unlock the potential of Avalo Therapeutics with AVTX-009, a promising drug for hidradenitis suppurativa. Oppenheimer upgrades to Outperform, foreseeing Phase 2 progress and market distinction. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.